These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33647441)

  • 41. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System.
    Fusaroli M; Raschi E; Gatti M; De Ponti F; Poluzzi E
    Front Pharmacol; 2021; 12():740707. PubMed ID: 34955821
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS).
    Yuan J; Li M; Yu Y; Lee TY; Lv G; Han B; Xiang X; Lu ZK
    Drugs Real World Outcomes; 2021 Jun; 8(2):131-140. PubMed ID: 33569736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
    Choudhury M; Dhanabalan AK; Goswami N
    J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
    Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
    Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance.
    Fallani E; Cevenini F; Lazzerini PE; Verdini A; Saponara S
    J Clin Pharmacol; 2022 May; 62(5):646-655. PubMed ID: 34802170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.
    Kim MS; Jung SY; Lee SW; Li H; Koyanagi A; Kronbichler A; Dragioti E; Tizaoui K; Wasuwanich P; Hong SH; Ghayda RA; Yoo HW; Kim H; Jacob L; Salem JE; Kostev K; Shin YH; Kim SY; Gamerith G; Yon DK; Shin JI; Smith L
    Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1970-1972.e3. PubMed ID: 33940227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.
    Hajimoradi M; Sharif Kashani B; Dastan F; Aghdasi S; Abedini A; Naghashzadeh F; Mohamadifar A; Keshmiri MS; Noorali S; Lookzadeh S; Alizadeh N; Siri MA; Tavasolpanahi M; Abdolmohammadi Y; Shafaghi M; Rouhani ZS; Shafaghi S
    Front Pharmacol; 2022; 13():1107198. PubMed ID: 36733376
    [No Abstract]   [Full Text] [Related]  

  • 50. Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports.
    Abdelmajid A; Osman W; Musa H; Elhiday H; Munir W; Al Maslamani MA; Elmekaty EZ
    IDCases; 2021; 26():e01254. PubMed ID: 34401329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS).
    Romão BMS; Duval FV; Lima EC; da Silva FAB; de Matos GC
    Front Pharmacol; 2024; 15():1349543. PubMed ID: 38370482
    [No Abstract]   [Full Text] [Related]  

  • 52. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
    Panovska-Stavridis I; Ridova N; Stojanoska T; Demiri I; Stevanovic M; Stojanovska S; Ristevska T; Dimkovski A; Filipce V; Dimovski A; Grozdanova A
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Apr; 42(1):5-18. PubMed ID: 33894123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate.
    Chen YZ; Lin MS; Lin YP; Liu YZ; Yang CJ
    J Microbiol Immunol Infect; 2023 Oct; 56(5):970-976. PubMed ID: 37407291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions.
    Sainz-Gil M; Merino Kolly N; Velasco-González V; Verde Rello Z; Fernandez-Araque AM; Sanz Fadrique R; Martín Arias LH
    Expert Opin Drug Saf; 2023 Jan; 22(1):71-79. PubMed ID: 35574687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
    ; Pan H; Peto R; Henao-Restrepo AM; Preziosi MP; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny MP; Malekzadeh R; Murthy S; Reddy KS; Roses Periago M; Abi Hanna P; Ader F; Al-Bader AM; Alhasawi A; Allum E; Alotaibi A; Alvarez-Moreno CA; Appadoo S; Asiri A; Aukrust P; Barratt-Due A; Bellani S; Branca M; Cappel-Porter HBC; Cerrato N; Chow TS; Como N; Eustace J; García PJ; Godbole S; Gotuzzo E; Griskevicius L; Hamra R; Hassan M; Hassany M; Hutton D; Irmansyah I; Jancoriene L; Kirwan J; Kumar S; Lennon P; Lopardo G; Lydon P; Magrini N; Maguire T; Manevska S; Manuel O; McGinty S; Medina MT; Mesa Rubio ML; Miranda-Montoya MC; Nel J; Nunes EP; Perola M; Portolés A; Rasmin MR; Raza A; Rees H; Reges PPS; Rogers CA; Salami K; Salvadori MI; Sinani N; Sterne JAC; Stevanovikj M; Tacconelli E; Tikkinen KAO; Trelle S; Zaid H; Røttingen JA; Swaminathan S
    N Engl J Med; 2021 Feb; 384(6):497-511. PubMed ID: 33264556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
    Montastruc JL; Toutain PL
    Drug Saf; 2020 Jul; 43(7):657-660. PubMed ID: 32495148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®).
    Batteux B; Bennis Y; Bodeau S; Masmoudi K; Hurtel-Lemaire AS; Kamel S; Gras-Champel V; Liabeuf S
    Bone; 2021 Dec; 153():116137. PubMed ID: 34343739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase.
    Macías Saint-Gerons D; Ibarz MT; Castro JL; Forés-Martos J; Tabarés-Seisdedos R
    Drugs Real World Outcomes; 2023 Jun; 10(2):263-270. PubMed ID: 36788170
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Remdesivir-induced Bradycardia is not Associated with Worse Outcome in Patients with COVID-19: A Retrospective Analysis.
    Pantazopoulos I; Mavrovounis G; Dimeas G; Zikos N; Pitsikou M; Rousogianni E; Mermiri M; Michou A; Spanos M; Maniotis C; Chalkias A; Laou E; Zakynthinos G; Chatzis D; Gourgoulianis K
    Am J Cardiovasc Drugs; 2022 Nov; 22(6):705-710. PubMed ID: 36002783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.